Michael Singer

Michael Singer, the Chairman and Chief Strategy Officer at Cartesian Therapeutics, a clinical-stage biotech company developing mRNA-engineered cell therapies, is also the Co-Founder and Chief Scientific Officer at Thirsty Brook Investments, a family investment firm. With a strong educational background from Yale University and Harvard Medical School, Michael serves on the Board of Directors for various companies such as Anodyne Nanotech, BioPorto Diagnostics, and Pykus Therapeutics. Additionally, Michael holds advisory roles at Cellens Inc and iVexSol, Inc. Michael also contributes their expertise as an Entrepreneur-in-Residence at Yale University and as part of the Scientific Advisory Board at the Yale School of Medicine.